FranchiseWire’s Post

👉What type of speciality ranges are available for PCD franchise on Rednirus Mart? Comment Down Your Answer 👇 #PCDPharma #PharmaFranchise #PCDfranchisebusiness #PCD #PCDPharma #pcd #FranchiseOpportunity #indiabusiness #HealthcareOpportunity #EntrepreneurshipJourney #MedicalIndustry

Unity Road – Your gateway to the booming cannabis sector. 🌱 Invest in a franchise that offers a complete business model with cannabis-related products and services. 💼 With an investment range of $1,000,000 to $2,500,000, we benefit from a proven system, ongoing support, and a recognized brand name. 📈 Join a growing market and become a part of the future of alternative health care. 🌿 Get leads today and start your journey with Unity Road! #UnityRoad #CannabisFranchise #InvestInCannabis #BusinessOpportunity #FranchiseInvestment #CannabisIndustry #AlternativeHealthcare #CannabisBusiness #ProvenBusinessModel #EntrepreneurLife #InvestmentOpportunity #CannabisMarket #JoinTheFuture #OngoingSupport #RecognizedBrand #GrowWithUs #CannabisCommunity #HealthAndWellness #FranchiseSuccess #InvestWisely

Unity Road – Your gateway to the booming cannabis sector. 🌱 Invest in a franchise that offers a complete business model with cannabis-related products and services. 💼 With an investment range of $1,000,000 to $2,500,000, we benefit from a proven system, ongoing support, and a recognized brand name. 📈 Join a growing market and become a part of the future of alternative health care. 🌿 Get leads today and start your journey with Unity Road! #UnityRoad #CannabisFranchise #InvestInCannabis #BusinessOpportunity #FranchiseInvestment #CannabisIndustry #AlternativeHealthcare #CannabisBusiness #ProvenBusinessModel #EntrepreneurLife #InvestmentOpportunity #CannabisMarket #JoinTheFuture #OngoingSupport #RecognizedBrand #GrowWithUs #CannabisCommunity #HealthAndWellness #FranchiseSuccess #InvestWisely

Available Now: NAVLIN by EVERSANA's “Last Week in Review,” recapping the latest regulatory changes, pricing & reimbursement updates, and drug approvals across the world. This week: Policy: Chairman of FPMAJ and Eisai's COO opposes full-scale price revisions in FY2025 in Japan. Pricing & Reimbursement: FDA authorizes Florida's prescription drug importation program, enabling the state to purchase from Canadian wholesalers. HTA: NICE recommends Opdivo and Opdualag for melanoma treatment in France and the UK. Drug Approval: MHRA approves Menarini Stemline UK’s Korserdu for ER+, HER2- advanced or metastatic breast cancer tumors with ESR1 mutations. Drug Launch: Eli Lilly launches LillyDirect, allowing direct ordering of prescribed drugs in the U.S. Supply Issues: OHE report identifies generic and biosimilar markets as central to drug shortages. Other: Blueprint Medicines discontinues BLU-945 and BLU-451 development for EGFR-mutant NSCLC. READ MORE: https://ow.ly/JzUf50QrgUw

Available Now: NAVLIN by EVERSANA's “Last Week in Review,” recapping the latest regulatory changes, pricing & reimbursement updates, and drug approvals across the world. This week: Policy: Gulf Health Council unifies medical product registration in GCC for streamlined processes. Pricing & Reimbursement: Major drugmakers like Pfizer, Sanofi, and Takeda plan price hikes for over 500 drugs in the US in January 2023. HTA: BMS' Breyanzi was recognized as cost-effective for treating r/r DLBCL in a study by the American Society of Hematology. Drug Approvals: FDA approves 55 new drugs in 2023, marking a 50% increase from 2022. Industry Deals & Agreements: Bristol Myers Squibb to acquire RayzeBio, bolstering cancer therapeutics pipeline with a USD 4.1 billion deal. READ MORE: https://ow.ly/f2gT50QoMCv

Available Now: NAVLIN by EVERSANA's “Last Week in Review,” recapping the latest regulatory changes, pricing & reimbursement updates, and drug approvals across the world. This week: Policy: Senate Finance Committee proposes bipartisan solutions to prevent and mitigate U.S. generic drug shortages. Pricing & Reimbursement: BeNeLuxA Initiative concludes joint pricing negotiations for Orchard Therapeutics' Libmeldy in Belgium, the Netherlands, and Ireland. HTA: France’s HAS grants pre-MA early access for Vertex’s Casgevy in transfusion-dependent ß thalassemia treatment. Drug Approval: EMA's CHMP debates extending Novo Nordisk's Wegovy use to reduce the risk of strokes and heart attacks. https://ow.ly/e5C050QvqHE

Available Now: NAVLIN by EVERSANA's “Last Week in Review,” recapping the latest regulatory changes, pricing & reimbursement updates, and drug approvals across the world. This week: Policy & Pricing: Explore how India's rejection of a 'data exclusivity' provision impacts the global pharmaceutical market, safeguarding domestic generics industry. HTA Insights: Gain valuable insights into Norway's streamlined access to immunotherapy and the positive recommendations for novel treatments in Italy and Sweden. Drug Approvals: Stay ahead of the curve with updates on FDA approvals, including Roche's PNH treatment in China and the European Commission's nod to Vertex's gene therapy. C&G Therapy Insights: Discover the latest advancements in CAR-T cell therapy with the commercial availability of NexCAR19 in India, revolutionizing cancer treatment. Conferences: NAVLIN DAILY is proud to be an official media partner of the World EPA Congress, bringing you cutting-edge insights into evidence, pricing, and access strategies in Amsterdam. And more... READ NOW: https://ow.ly/aUi750QFnLw

DRUG PRICE CONTROL CHINA STYLE "it was found that Shanghai Pharmaceuticals No.1 Biopharmaceutical worked with Hubei Minkang Pharmaceutical, Wuhan Kede Pharmaceutical, and Wuhan Huihai Pharmaceutical hundreds of times to artificially raise the prices of raw materials. At the same time, the companies altered the domestic price of Injection Sulfated Polymyxin B to exceed CNY 2303 per vial, making it multiple times more expensive than prices overseas. In order to protect the interests and rights of patients, the NHSA carried out two consultations with Shanghai Pharmaceuticals to discuss the artificial price revisions. As a result, the net price of the drug was cut to CNY 123 per vial which is estimated to reduce costs by more than CNY 3.8 billion per year." #china #drugs #pharmaceuticals #pricecontrol #ha #bio #efpia #cmo #cro https://lnkd.in/eQxW2aW7

Will MFN be implemeted in the US ? As we head toward the 2024 U.S. election, Donald Trump’s campaign has confirmed plans to revive the controversial Most Favored Nations (MFN) pharmaceutical pricing model. If this goes forward, it could introduce an international reference pricing system where the U.S. pays the lowest price among OECD nations. 💊 This move could shake up the entire pharmaceutical landscape, with potential consequences for innovation and R&D leadership in the U.S. 🔍 How could this could impact the global pharma industry? Are we looking at a game-changer for market access, or are the risks too great? Read more on NAVLIN DAILY: https://lnkd.in/gaUsBvEd And feel free to ask the NAVLIN team to run a simulation on your product portfolio! #PharmaPricing #DrugPolicy #MarketAccess #Innovation #PharmaLeadership #Election2024

Available Now: NAVLIN by EVERSANA's “Last Week in Review,” recapping the latest regulatory changes, pricing & reimbursement updates, and drug approvals across the world. This week: Policy: The bipartisan bill proposed by Senators Ron Wyden and Mike Crapo aims to combat generic medicine shortages in the U.S. by incentivizing players in the prescription drug supply chain and modifying the Medicaid Drug Rebate Program (MDRP). Pricing & Reimbursement: The Centers for Medicare & Medicaid Services (CMS) published draft guidance on the second cycle of negotiations under the Inflation Reduction Act’s Medicare Drug Price Negotiation Program. HTA: France’s High Authority for Health (HAS) granted a pre-MA early access scheme for treating adult patients with paroxysmal nocturnal hemoglobinuria (PNH) who have hemolytic anemia (Hb < 10g/dL) following treatment with a complement C5 inhibitor for at least six months. Drug Approval: India’s drug regulatory body updated approval processes for pharmaceutical exports to meet WHO’s Good Manufacturing Practices (GMP) certification standards. C&G Therapy: The first U.S. patients have begun the medical preparation needed to receive Vertex Pharmaceuticals' and bluebird bio's recently approved gene therapies for sickle cell disease. Conferences: At ISPOR 2024, Riku Ota, MPH, Novo Nordisk, København, Denmark, warned that a lack of consideration of health equity in HTA could limit access to treatments and cause misalignments in resource allocation. And more... READ MORE: https://ow.ly/Tpq250REhNO